HC Wainwright Issues Negative Outlook for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Nuvalent in a report issued on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($1.21) per share for the quarter, down from their prior forecast of ($1.08). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($4.66) EPS and FY2026 earnings at ($3.26) EPS.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02).

NUVL has been the subject of several other reports. Wedbush reiterated an “outperform” rating and set a $115.00 price objective on shares of Nuvalent in a research report on Monday, January 13th. BMO Capital Markets upped their target price on Nuvalent from $132.00 to $134.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $113.10.

Nuvalent Trading Up 0.8 %

Shares of NASDAQ NUVL opened at $71.61 on Wednesday. The stock has a 50 day simple moving average of $79.90 and a 200-day simple moving average of $88.51. The company has a market cap of $5.09 billion, a PE ratio of -20.64 and a beta of 1.38. Nuvalent has a 12-month low of $61.80 and a 12-month high of $113.51.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $78.43, for a total value of $156,860.00. Following the transaction, the director now owns 216,522 shares of the company’s stock, valued at approximately $16,981,820.46. This represents a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alexandra Balcom sold 4,016 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $79.68, for a total value of $319,994.88. Following the completion of the transaction, the chief financial officer now directly owns 61,734 shares in the company, valued at $4,918,965.12. This represents a 6.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,800 shares of company stock valued at $8,895,004. Corporate insiders own 12.52% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

Several institutional investors and hedge funds have recently modified their holdings of the stock. Crowley Wealth Management Inc. bought a new stake in Nuvalent in the fourth quarter worth $27,000. Quarry LP bought a new stake in Nuvalent in the fourth quarter worth $39,000. US Bancorp DE bought a new stake in Nuvalent in the fourth quarter worth $90,000. GF Fund Management CO. LTD. bought a new stake in Nuvalent in the fourth quarter worth $108,000. Finally, KBC Group NV boosted its holdings in Nuvalent by 61.1% in the fourth quarter. KBC Group NV now owns 1,587 shares of the company’s stock worth $124,000 after purchasing an additional 602 shares in the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.